Physicians and Clinicians

Dr. Curtis A. Clark

Curtis A. Clark, M.D., Ph.D. is a radiation oncologist with Clearview Cancer Institute, providing comprehensive cancer care across North Alabama.

Dr. Clark earned his undergraduate (B.S.) and graduate (M.S.) degrees from The University of Texas at Tyler, where he served as president of the Tri-Beta Biological Honor Society and was a member of the collegiate basketball and cross-country teams. He went on to complete a combined M.D./Ph.D. at The University of Texas Health Science Center at San Antonio through the NIH-designated Medical Scientist Training Program, where his research focused on immune checkpoint regulation and novel therapeutic targets in cancer.

He completed residency training in radiation oncology at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, where he served as Chief Resident.

Dr. Clark has a strong background in translational and clinical research, with a focus on immuno-oncology and the integration of systemic therapies with radiation. He was selected for the American Board of Radiology Holman Research Pathway, where his work centered on immunotherapy, DNA damage response signaling, and combined modality treatment approaches. He has authored peer-reviewed publications in high-impact journals and presented his work at national and international meetings, and remains actively engaged in advancing evidence-based cancer care.

In addition to his clinical practice, Dr. Clark is actively involved in regional oncology leadership and multidisciplinary collaboration. He serves as a board member of the Alabama Cancer Congress and has worked to expand the integration of radiation oncology within statewide cancer initiatives. He has helped develop multidisciplinary tumor boards and referral networks to improve access, coordination, and quality of cancer care across the region.

Clinically, Dr. Clark treats a broad range of malignancies and has expertise in advanced radiation techniques, including stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS), intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and high-dose-rate (HDR) brachytherapy. His approach emphasizes precision, safety, and personalization—leveraging modern technology and evidence-based strategies to optimize outcomes while minimizing toxicity.

He is committed to a patient-centered, multidisciplinary model of care and values close collaboration with medical oncology, surgical oncology, and subspecialists to ensure each patient receives thoughtful, individualized treatment.